Skip to Content

Kyprolis Side Effects

Generic Name: carfilzomib

Note: This document contains side effect information about carfilzomib. Some of the dosage forms listed on this page may not apply to the brand name Kyprolis.

In Summary

Common side effects of Kyprolis include: asthenia, arthralgia, dyspnea, fever, thrombocytopenia, vomiting, and chills. Other side effects include: congestive heart failure, pulmonary edema, and reduced ejection fraction. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to carfilzomib: intravenous powder for solution

Along with its needed effects, carfilzomib (the active ingredient contained in Kyprolis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking carfilzomib:

More common
  • Agitation
  • black, tarry stools
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blood in the urine or stools
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain
  • coma
  • confusion
  • cough or hoarseness
  • decreased urine output
  • depression
  • difficult or labored breathing
  • difficulty with moving
  • dizziness
  • drowsiness
  • fast, slow, or irregular heartbeat
  • headache
  • hostility
  • irregular heartbeat
  • irritability
  • lower back or side pain
  • muscle spasms (tetany) or twitching
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • rapid weight gain
  • seizures
  • stupor
  • tightness in the chest
  • tingling of the hands or feet
  • trembling
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • unusual tiredness or weakness
  • unusual weight gain or loss
Less common
  • Chills
  • fever
  • muscle pain or cramps
  • painful blisters on the trunk of the body
  • weakness in the arms, hands, legs, or feet
  • Dark-colored urine
  • general feeling of discomfort or illness
  • general feeling of tiredness or weakness
  • light-colored stools
  • stomach pain, continuing
  • thickening of bronchial secretions
  • yellow eyes or skin
Incidence not known
  • Blindness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • joint pain, stiffness, or swelling
  • stomach pain
  • sweating

Some side effects of carfilzomib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Back pain
  • body aches or pain
  • bone pain
  • constipation
  • diarrhea
  • dry mouth
  • ear congestion
  • flushed, dry skin
  • fruit-like breath odor
  • increased hunger
  • increased thirst
  • increased urination
  • loss of appetite
  • loss of voice
  • metallic taste
  • muscle weakness
  • pain in the arms or legs
  • runny nose
  • sneezing
  • sore throat
  • trouble sleeping
  • weight loss

For Healthcare Professionals

Applies to carfilzomib: intravenous powder for injection


Very common (10% or more): Anemia (47%), thrombocytopenia (36%), lymphopenia (24%), neutropenia (21%), leukopenia (14%)
Common (1% to 10%): Deep vein thrombosis
Uncommon (0.1% to 1%): Hemolytic uremic syndrome (HUS)
Rare (less than 0.1%): Thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, hemorrhage[Ref]


Very common (10% or more): Hypertension (14%)
Common (1% to 10%): Cardiac failure (i.e., pulmonary edema, decreased ejection fraction), atrial fibrillation, tachycardia, palpitations, flushing
Uncommon (0.1% to 1%): Cardiac arrest, myocardial infarction, myocardial ischemia, pericarditis, pericardial effusion
Rare (less than 0.1%): Hypertensive crisis[Ref]


Very common (10% or more): Increased aspartate aminotransferase (13%)
Common (1% to 10%): Increased alanine aminotransferase, increased gamma-glutamyltransferase, hyperbilirubinemia
Uncommon (0.1% to 1%): Hepatic failure, cholestasis[Ref]

Nervous system

Very common (10% or more): Headache (28%), peripheral neuropathy (14%), dizziness (13%), hypoesthesia (12%), dizziness
Postmarketing reports: Posterior reversible encephalopathy syndrome, paresthesia, hypoesthesia
Uncommon (0.1% to 1%): Intracranial hemorrhage, cerebrovascular accident
Rare (less than 0.1%): Posterior reversible encephalopathy syndrome (PRES)[Ref]


Very common (10% or more): Fatigue (56%), pyrexia (30%), peripheral edema (24%), chills (16%), arthralgia (16%), asthenia (14%), pain (12%), infusion reaction
Common (1% to 10%): Dysphonia
Uncommon (0.1% to 1%): Multi-organ failure[Ref]


Very common (10% or more): Dyspnea (35%), upper respiratory tract infection (28%), cough (26%), pneumonia (13%), nasopharyngitis
Common (1% to 10%): Pulmonary hypertension, bronchitis, pulmonary embolism, pulmonary edema, epistaxis, rhinitis, wheezing
Uncommon (0.1% to 1%): Lung infection
Rare (less than 0.1%): Acute respiratory distress syndrome (ARDS), acute respiratory failure, pulmonary hemorrhage, interstitial lung disease, pneumonitis[Ref]


Very common (10% or more): Nausea (45%), diarrhea (33%), vomiting (22%), constipation (21%), abdominal pain
Common (1% to 10%): Oropharyngeal pain, dyspepsia, toothache
Rare (less than 0.1%): GI hemorrhage, GI perforation[Ref]


Very common (10% or more): Increased blood creatinine (24%)
Common (1% to 10%): Acute renal failure, renal failure, renal impairment, decreased creatinine renal clearance[Ref]


Very common (10% or more): Hypokalemia (14%), hypomagnesemia (14%), anorexia (12%), hyperglycemia (12%), hypercalcemia (11%), hypophosphatemia (11%), hyponatremia (10%)
Common (1% to 10%): Dehydration, hyperkalemia, hypocalcemia, hyperuricemia, hypoalbuminemia
Uncommon (0.1% to 1%): Tumor lysis syndrome[Ref]


Very common (10% or more): Back pain (20%), extremity pain (13%), chest wall pain (11%), arthralgia, muscle spasms
Common (1% to 10%): Musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, muscular weakness[Ref]


Very common (10% or more): Insomnia (17.9%)
Common (1% to 10%): Anxiety[Ref]


Common (1% to 10%): Herpes zoster reactivation, sepsis, influenza, viral infection[Ref]


Common (1% to 10%): Rash, pruritus, erythema, hyperhidrosis[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Uncommon (0.1% to 1%): Drug hypersensitivity[Ref]


Common (1% to 10%): Cataract, blurred vision
Frequency not reported: Blindness and other adverse visual disturbances (due to PRES)[Ref]


1. "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc, South San Francisco, CA.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Some side effects of Kyprolis may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.